3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Prostatic Neoplasms
10
Carcinoma, Non-Small-Cell Lung
5
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Uterine Cervical Dysplasia
3
Glioma
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Brain Neoplasms
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Rectal Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Oropharyngeal Neoplasms
2
Neoplasms
2
Mouth Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Ependymoma
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Ureteral Neoplasms
1
Thyroid Nodule
1
Interventions
pembrolizumab
4
Nivolumab
4
fludarabine
3
aldesleukin
3
Ipilimumab
3
Cyclophosphamide
3
vedolizumab
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
atezolizumab
2
Specimen Handling
2
Riluzole
2
Prednisone
2
Magnetic Resonance Spectroscopy
2
LDP-02
2
Infliximab
2
Immunoglobulin G
2
Fecal Microbiota Transplantation
2
Disulfides
2
CTLA-4 Antigen
2
CT-P13
2
Biopsy
2
relatlimab
1
prednylidene
1
palbociclib
1
olaparib
1
gallium 68 PSMA-11
1
deltacortene
1
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Watchful Waiting
×
1 year
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled